Latest Insider Transactions at Oncology Institute, Inc. (TOI)
This section provides a real-time view of insider transactions for Oncology Institute, Inc. (TOI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Oncology Institute, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Oncology Institute, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 31
2025
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
157,088
+39.95%
|
-
|
|
Mar 31
2025
|
Robert Ross Carter Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
197,368
+45.46%
|
-
|
|
Mar 31
2025
|
Jeremy Castle Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
162,281
+39.11%
|
-
|
|
Mar 31
2025
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,083,334
+37.47%
|
-
|
|
Mar 26
2025
|
M33 Growth I L.P. Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,716,898
+14.2%
|
$2,716,898
$1.04 P/Share
|
|
Mar 26
2025
|
Daniel Virnich Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
22,640
+3.03%
|
$22,640
$1.04 P/Share
|
|
Mar 26
2025
|
Yale Podnos Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+10.28%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Mark L Pacala Director |
BUY
Open market or private purchase
|
Indirect |
90,562
+28.7%
|
$90,562
$1.04 P/Share
|
|
Mar 26
2025
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
9,056
+1.32%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Karen Marie Johnson Director |
BUY
Open market or private purchase
|
Direct |
36,224
+15.12%
|
$36,224
$1.04 P/Share
|
|
Mar 26
2025
|
Jeremy Castle Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+9.11%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Richard A Barasch Director |
BUY
Open market or private purchase
|
Indirect |
1,358,448
+43.34%
|
$1,358,448
$1.04 P/Share
|
|
Mar 26
2025
|
Robert Ross Carter Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+18.69%
|
$9,056
$1.04 P/Share
|
|
Mar 19
2025
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,261
-1.44%
|
$0
$0.89 P/Share
|
|
Mar 19
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,150
-3.65%
|
$0
$0.89 P/Share
|
|
Mar 19
2025
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,975
-4.08%
|
$0
$0.89 P/Share
|
|
Jan 06
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
258
-0.81%
|
$0
$0.34 P/Share
|
|
Dec 03
2024
|
Jeremy Castle Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,130
-1.37%
|
$0
$0.16 P/Share
|
|
Dec 02
2024
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
50,000
+6.98%
|
$0
$0.15 P/Share
|
|
Nov 26
2024
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
250,000
+28.84%
|
$0
$0.17 P/Share
|
|
Nov 22
2024
|
Richard A Barasch Director |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+16.09%
|
-
|
|
Nov 22
2024
|
Mark L Pacala Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+27.11%
|
-
|
|
Nov 22
2024
|
Karen Marie Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,000
+23.72%
|
-
|
|
Nov 22
2024
|
Anne Mc George Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,000
+23.4%
|
-
|
|
Nov 22
2024
|
Gabriel Ling Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+26.84%
|
-
|
|
Nov 22
2024
|
Mohit Kaushal Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,000
+24.01%
|
-
|
|
Nov 22
2024
|
Brad Hively Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+5.76%
|
-
|
|
Nov 20
2024
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,002
-1.33%
|
$0
$0.14 P/Share
|
|
Nov 20
2024
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
235
-0.73%
|
$0
$0.14 P/Share
|
|
Nov 20
2024
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,727
-0.68%
|
$0
$0.14 P/Share
|
|
Nov 12
2024
|
Brad Hively Director |
SELL
Other acquisition or disposition
|
Direct |
353,450
-49.08%
|
-
|
|
Nov 12
2024
|
Yale Podnos Chief Medical Officer |
SELL
Other acquisition or disposition
|
Direct |
28,398
-14.6%
|
-
|
|
Nov 12
2024
|
Daniel Virnich Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
195,236
-11.24%
|
-
|
|
Nov 12
2024
|
Mark L Pacala Director |
SELL
Other acquisition or disposition
|
Direct |
50,620
-20.73%
|
-
|
|
Aug 16
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
16,333,241
-74.63%
|
-
|
|
Jun 17
2024
|
Brad Hively Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,121
-2.61%
|
$0
$0.46 P/Share
|
|
May 22
2024
|
Brad Hively Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,526
-2.74%
|
$0
$0.58 P/Share
|
|
May 21
2024
|
Jeremy Castle Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,120
+45.96%
|
-
|
|
May 21
2024
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,530
+14.38%
|
-
|
|
May 21
2024
|
Mihir Shah Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
151,459
+24.18%
|
-
|
|
May 21
2024
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
198,517
+17.8%
|
-
|
|
May 21
2024
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,173
-1.53%
|
$0
$0.6 P/Share
|
|
Jan 29
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
8,637
-100.0%
|
$17,274
$2.12 P/Share
|
|
Jan 26
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
6,979
-44.69%
|
$13,958
$2.14 P/Share
|
|
Jan 25
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
11,882
-43.21%
|
$23,764
$2.07 P/Share
|
|
Jan 24
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
24,915
-47.54%
|
$49,830
$2.3 P/Share
|
|
Jan 23
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
5,338
-9.24%
|
$10,676
$2.11 P/Share
|
|
Jan 22
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
10,263
-15.09%
|
$20,526
$2.12 P/Share
|
|
Jan 19
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
11,986
-14.98%
|
$23,972
$2.13 P/Share
|
|
Dec 28
2023
|
Havencrest Healthcare Partners, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
8,561,048
-28.66%
|
-
|